Protara Therapeutics, Inc. (TARA) Stock Forecast
TARA analyst forecast
as of October 18, 2026- Analyst consensus
- Strong buy 4.75 / 5 from 8 analysts
- Price target
- $25.71 average of analyst targets
- Upside to target
- +1,008.4% from the latest close
- Next earnings
- November 9, 2026 EPS estimate $-0.37
- 52-week range
- $2.32 – $7.56
TARA analyst ratings
8 analystsNumber of analysts at each rating.
TARA price target
The average of analyst 12-month price targets compared with the latest close and the 52-week range.
TARA earnings per share estimates
| Period | Average | Low | High | Year ago | Growth | Analysts |
|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.36 | −$0.38 | −$0.34 | −$0.31 | −17.1% | 6 |
| Current fiscal year (2026) | −$1.39 | −$1.46 | −$1.31 | −$1.34 | −4.0% | 6 |
| Next fiscal year (2027) | −$1.69 | −$2.25 | −$1.13 | −$1.39 | −21.4% | 7 |
Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.
TARA revenue estimates
| Period | Average | Low | High | Growth | Analysts |
|---|---|---|---|---|---|
| Current quarter (Sep '26) | $0 | $0 | $0 | 0.0% | 6 |
| Current fiscal year (2026) | $0 | $0 | $0 | 0.0% | 7 |
| Next fiscal year (2027) | $1.0M | $0 | $7.0M | 0.0% | 7 |
TARA EPS: reported and forecast
Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.
TARA revenue: reported and forecast
TARA EPS estimate revisions
| Period | 90 days ago | 60 days ago | 30 days ago | 7 days ago | Now | Change (90 d) | Revisions (30 d) |
|---|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.33 | −$0.36 | −$0.36 | −$0.36 | −$0.36 | +9.7% | 0 up · 3 down |
| Current fiscal year (2026) | −$1.39 | −$1.39 | −$1.39 | −$1.39 | −$1.39 | +0.4% | 0 up · 5 down |
| Next fiscal year (2027) | −$1.64 | −$1.69 | −$1.69 | −$1.69 | −$1.69 | +2.9% | 1 up · 3 down |
How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.
TARA earnings surprises
Reported EPS vs the consensus estimate for the last 12 quarters; TARA beat in 9 of 12.
What analysts expect from TARA
8 analysts cover Protara Therapeutics; their consensus rating is strong buy (4.75 on a 1–5 scale, where 5 is a strong buy). The average price target is $25.71, 1,008.4% above the latest close of $2.32. Analysts expect earnings of −$1.39 per share for 2026, −4.0% from a year earlier. For 2027 the average estimate is −$1.69 per share on revenue of $1.0 million. Protara Therapeutics beat the EPS estimate in 9 of the last 12 quarters.
Related: TARA income statement, TARA key metrics, TARA chart. See the TARA stock overview for the latest quote and news.
TARA forecast FAQ
What is Protara Therapeutics's price target?
The average analyst price target for Protara Therapeutics is $25.71, 1,008.4% above the latest close of $2.32.
Is Protara Therapeutics a buy, hold or sell?
Of 8 analysts covering Protara Therapeutics, 6 rate it a strong buy, 2 a buy, 0 a hold, 0 a sell and 0 a strong sell, a consensus of strong buy. Ratings are opinions, not a recommendation from Quotelinks.
What is Protara Therapeutics's EPS forecast?
Analysts forecast −$1.39 per share for 2026 (range −$1.46 to −$1.31); for 2027 the estimate is −$1.69.
When does Protara Therapeutics report earnings?
Protara Therapeutics is expected to report results for the quarter ending September 30, 2026 on November 9, 2026; the EPS estimate is $-0.37.
Does Protara Therapeutics usually beat earnings estimates?
Protara Therapeutics reported EPS at or above the analyst estimate in 9 of the last 12 quarters.